Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 2
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

3 results

Results by year

Filters applied: . Clear all
Page 1
Second primary malignancies in patients with haematological cancers treated with lenalidomide: a systematic review and meta-analysis.
Saleem K, Franz J, Klem ML, Yabes JG, Boyiadzis M, Jones JR, Shaikh N, Lontos K. Saleem K, et al. Lancet Haematol. 2022 Dec;9(12):e906-e918. doi: 10.1016/S2352-3026(22)00289-7. Epub 2022 Oct 27. Lancet Haematol. 2022. PMID: 36354020
Thus, lenalidomide can be used for other indications without the major concern of a therapy-related neoplasm. In the multiple myeloma setting, lenalidomide is an effective drug, but patients should be monitored both for haematological and solid tumour SPM. .. …
Thus, lenalidomide can be used for other indications without the major concern of a therapy-related neoplasm. In the mu …
A 14-year retrospective analysis of indications and outcomes of autologous haemopoietic stem cell transplantation in regional Queensland: a single-centre experience.
Hamilton EM, Nath KD, Vangaveti VN, McCutchan AD, Marsh JL, Birchley AJ, Casey JM, McNamara C, Lai HC, Morris ES, Hodges G, Irving IM. Hamilton EM, et al. Intern Med J. 2020 Feb;50(2):214-221. doi: 10.1111/imj.14395. Intern Med J. 2020. PMID: 32037713
Key outcomes included overall survival, non-relapse mortality, incidence of therapy-related neoplasm and causes of death. Progression-free survival in the multiple myeloma (MM) subgroup was also assessed. ...
Key outcomes included overall survival, non-relapse mortality, incidence of therapy-related neoplasm and causes of deat …